Is sertraline appropriate for treating body dysmorphic disorder in an adult patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sertraline is an appropriate and evidence-based first-line pharmacological treatment for body dysmorphic disorder (BDD) in adults.

SSRIs, including sertraline, are the medication of choice for treating BDD, though this represents off-label use as BDD is not an FDA-approved indication 1. Despite the lack of formal FDA approval for BDD specifically, sertraline's FDA-approved indications for obsessive-compulsive disorder (OCD) are particularly relevant, as BDD shares substantial phenomenological overlap with OCD and was reclassified in DSM-5 under "Obsessive-Compulsive and Related Disorders" 2.

Evidence Supporting Sertraline for BDD

The evidence base for SSRIs in BDD treatment is substantial:

  • SSRIs demonstrate the greatest improvement in BDD symptoms with a standardized mean difference of -1.16 in reducing depressive symptoms associated with BDD 3
  • Multiple systematic reviews confirm that SSRIs substantially reduce core BDD symptoms, improve psychosocial functioning, quality of life, and reduce suicidality 4, 5
  • Both pharmacological treatment and cognitive behavioral therapy show large effect sizes, with SSRIs yielding a pooled effect of -0.96 (95% CI [-1.37,-0.54], p < 0.001) 3

Critical Prescribing Considerations

Dosing Requirements

BDD typically requires higher SSRI doses than depression or other anxiety disorders 5. Start sertraline at 50 mg daily and titrate upward as tolerated, often requiring doses of 150-200 mg daily or higher to achieve therapeutic benefit 4. This differs from depression treatment where lower doses may suffice.

Treatment Duration

  • Allow 8-12 weeks minimum to assess efficacy - BDD often requires protracted periods to establish full benefit 5
  • Improvement may begin within the first 2 weeks, but maximal gains occur with continued treatment 6
  • Long-term maintenance is typically necessary; premature discontinuation often leads to relapse 4

Common Pitfalls to Avoid

  1. Underdosing: Using depression-level doses (50-100 mg) rather than the higher doses often needed for BDD (150-200+ mg)

  2. Premature discontinuation: Stopping treatment before 8-12 weeks when initial response seems inadequate

  3. Missing the diagnosis: BDD patients often present seeking cosmetic procedures rather than psychiatric treatment. Screen with validated instruments and ask specifically about appearance preoccupations and associated repetitive behaviors (mirror checking, skin picking, reassurance seeking) 7, 2

  4. Ignoring suicidality: BDD carries exceptionally high suicide risk (11-44% attempt history in clinical samples). Conduct thorough suicide risk assessment before initiating treatment 7

When Sertraline Alone Is Insufficient

If inadequate response after 12 weeks at therapeutic doses:

  • Consider augmentation with atypical antipsychotics (though evidence is limited and this is off-label) 8, 5
  • Add cognitive behavioral therapy - combined treatment may provide optimal outcomes 3, 5
  • Trial alternative SSRIs (fluoxetine, escitalopram) or clomipramine 6, 5
  • Consider adjunctive anxiolytics or levetiracetam for treatment-resistant cases 5

Monitoring Requirements

  • Monitor for increased suicidality, particularly in the first weeks of treatment, as SSRIs carry increased risk for nonfatal suicide attempts (OR 1.57-2.25) 9
  • Assess for common SSRI adverse effects: nausea (most common reason for discontinuation), diarrhea (sertraline has higher rates than other SSRIs), sexual dysfunction, insomnia, and somnolence 9
  • Sertraline causes more diarrhea than other SSRIs but has lower rates of sexual dysfunction than paroxetine 9

Integration with Psychotherapy

Cognitive behavioral therapy specifically tailored for BDD should be offered concurrently or sequentially 2, 5. CBT for BDD must address BDD-specific features including mirror use, perceptual distortions, misinterpretation of others' reactions, and overvalued ideas about appearance 5. Standard CBT protocols for depression or anxiety are insufficient.

Special Populations

For adolescents with BDD, the evidence base is more limited but emerging data support SSRI use with appropriate monitoring 2. Early-onset BDD (adolescence) carries increased risk for comorbidities and suicide, making early recognition and treatment particularly critical 10.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.